1-3 of 3
Adi Zoref-Lorenz
Close
Sort by
Journal Articles

Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab

Clinical Trials & Observations
Shanmuganathan Chandrakasan, Michael B. Jordan, Ashley Baker, Edward M. Behrens, Deepika Bhatla, May Chien, Olive S. Eckstein, Michael M. Henry, Michelle L. Hermiston, Ashley P. Hinson, Jennifer W. Leiding, Abiola Oladapo, Sachit A. Patel, Priti Pednekar, Anish K. Ray, Blachy Dávila Saldaña, Susmita N. Sarangi, Kelly J. Walkovich, John D. Yee, Adi Zoref-Lorenz, Carl E. Allen
Journal: Blood Advances
Blood Adv (2024) 8 (9): 2248–2258.
https://doi.org/10.1182/bloodadvances.2023012217
Published: 2024
Includes: Supplemental data
Journal Articles

Early response markers predict survival after etoposide-based therapy of hemophagocytic lymphohistiocytosis

Clinical Trials & Observations
Bethany Verkamp, Adi Zoref-Lorenz, Brenton Francisco, Pearce Kieser, Joana Mack, Tucker Blackledge, Dafna Brik Simon, Joanne Yacobovich, Michael B. Jordan
Journal: Blood Advances
Blood Adv (2023) 7 (23): 7258–7269.
https://doi.org/10.1182/bloodadvances.2023010546
Published: 2023
Includes: Supplemental data
Journal Articles

Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT

Ashley V. Geerlinks, Brooks Scull, Christa Krupski, Ryan Fleischmann, Michael A. Pulsipher, Mary Eapen, James A. Connelly, Catherine M. Bollard, Sung-Yun Pai, Christine N. Duncan, Leslie S. Kean, K. Scott Baker, Lauri M. Burroughs, Jeffrey R. Andolina, Shalini Shenoy, Philip Roehrs, Rabi Hanna, Julie-An Talano, Kirk R. Schultz, Elizabeth O. Stenger, Howard Lin, Adi Zoref-Lorenz, Kenneth L. McClain, Michael B. Jordan, Tsz-Kwong Man, Carl E. Allen, Rebecca A. Marsh
Journal: Blood Advances
Blood Adv (2023) 7 (14): 3725–3734.
https://doi.org/10.1182/bloodadvances.2022009478
Published: 2023
Includes: Supplemental data